Stock info Innate Pharma | Filter  Basic-Info

Innate Pharma

The past year gave good returns for Innate Pharma investors

Over the past year the company' stock gained around 9 percent. The period between August 2011 and August 2016 was a profitable period for the investors. The stock rose on average 945 percent. Innate Pharma's revenues between 2011 and 2015 were very volatile and moved between 10,38 million euros and 17,91 million euros. Innate Pharma's net results between 2011 and 2015 were very constant and moved between -6,98 million euros and -6,71 million euros.

The core activities of Innate Pharma are in the biotech sector. Between 2006 and 2016 the global biotech companies gained around 59 percent. As from 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

Innate Pharma didn't pay out any dividends (in the past 5 years).

Innate Pharma financed with relatively low debt

At the end of 2015 the French company's balance sheet was worth 305,96 million euros. The total debt was around 233,89 million euros. This is 76,44 percent of the total balance sheet.

At the end of 2015 the French company had around 53,4 million stocks listed.

All Innate Pharma's annual reports can be found here. More information about Innate Pharma can be found it's website. .